SynthesisInternational journal of nanomedicine2025
Chitosan Nanoparticles as an Alternative Therapeutic Approach for Knee Osteoarthritis Treatment: A Systematic Review.
Synthesis in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Effect of Medical Chitosan on Clinical Efficacy and Pain in Knee Osteoarthritis: A Systematic Review and Meta-Analysis.Diseases (Basel, Switzerland) · 2026Review
- Neoagarohexaose Attenuates Inflammatory and Oxidative Joint Injury in MIA/CIOA Mouse Models of Osteoarthritis.International journal of molecular sciences · 2026Article
- Review
- Recent advances in nanomaterial-based strategies for chronic pain alleviation.Materials today. Bio · 2026Review
- Micro-nano integrated platforms for osteoarthritis therapy: From spatial manipulation to cellular reprogramming.Materials today. Bio · 2026Review
- L-Arginine-Modified Chitosan Curcumin Nanocrystals Target M1 Macrophages via CAT-2/Clathrin-Mediated Endocytosis for Mitochondrial Protection and ALI/ARDS Therapy.Pharmaceutics · 2026Article
- Nanotechnology for pain management in orthopedic surgery.World journal of orthopedics · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a prevalent degenerative joint disease characterized by the progressive breakdown of cartilage, leading to pain, inflammation, and reduced joint function. There are many variations of conventional therapies that exist, however, none proven to halt or reverse cartilage degradation. Chitosan, a biocompatible and biodegradable polysaccharide, has emerged as a promising candidate in OA treatment due to its chondroprotective properties, and ability to enhance chondrocyte proliferation and suppress inflammatory mediators. Recent advancements in nanotechnology have led to the development of chitosan nanoparticles (NPs), which offer a novel and effective approach for addressing the limitations associated with standard chitosan formulations, such as poor solubility and limited tissue penetration. Chitosan NPs have demonstrated superior bioavailability, sustained drug release, and targeted delivery, leading to improved therapeutic outcomes in preclinical models. This review explores evidence-based the therapeutic potential of chitosan NPs in the management of knee osteoarthritis, focusing on their role in cartilage regeneration and drug delivery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.